NON SMALL CELL LUNG CANCER

This early-stage trial tests a new vaccine called IMP3-saRNA (YMN-136) in 9 people with advanced non-small cell lung cancer who have run out of standard options. The vaccine uses self-amplifying RNA to train the immune system to attack cancer cells. The main goal is to check safe…

This study looks at whether early heart monitoring and treatment can help people with advanced lung cancer who are receiving strong cancer therapies. About 524 adults with stage III non-small cell lung cancer will be enrolled. The goal is to see if this approach improves survival…

This study tests whether combining ivonescimab with either Dato-DXd or osimertinib is safe and works for people with advanced EGFR-mutant non-small cell lung cancer that has stopped responding to standard treatments. About 66 participants will receive different doses to find the …

This early-phase trial tests a new drug called ZM008, alone and with another drug (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find a safe dose and check for side effects. About 100 adults with cancer…

This study tests a new drug, SAR445877, in people with advanced non-small cell lung cancer that has stopped responding to immunotherapy. The goal is to see if the drug can help control the cancer. About 29 adults will take part, and researchers will monitor safety and side effect…

This study tests whether a lower dose of chemotherapy combined with an immunotherapy drug can be a safer and still effective first treatment for older adults (70+) or those who are frail with advanced non-small cell lung cancer. The main goal is to see if fewer people have to sto…

This study tests a new drug, izalontamab brengitecan, against standard chemotherapy for people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer) that has worsened after initial targeted therapy. About 500 participants will be randomly assigned to recei…

This study tests a new drug, taletrectinib, against the current standard drug crizotinib in people with a specific type of advanced lung cancer (ROS1-positive NSCLC) who have not had targeted therapy before. About 194 participants will be randomly assigned to take either taletrec…

This study tests an experimental pill called sutetinib in people with advanced lung cancer that has certain uncommon gene changes (EGFR mutations). The goal is to see if the drug can shrink tumors and control the disease. About 99 adults who have had no more than one prior chemot…

This early-stage trial tests a new drug called MDX2001 in about 285 people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. This is a first-in-human study, so researchers are also finding the best dose to …

This study tests whether adding a new drug (Sigvotatug Vedotin) to standard immunotherapy (pembrolizumab) helps people with advanced non-small cell lung cancer that has high PD-L1 levels. About 714 participants will receive either the combo or pembrolizumab alone. The goal is to …

This study tests a personalized gene therapy for people with metastatic cancers that haven't responded to standard treatments. Doctors take a patient's own white blood cells, genetically modify them in a lab to recognize and attack unique mutations in their tumor, then infuse the…

This study tests whether adding the experimental drug ivonescimab to standard chemotherapy (docetaxel) helps people with advanced non-small cell lung cancer whose disease has worsened after prior immunotherapy. About 536 adults aged 18 to 75 with good performance status will be r…

This early-stage trial tests a new drug called AU-007 in people with advanced solid tumors that have not responded to other treatments. AU-007 is designed to help the immune system fight cancer more effectively. The study will test the drug alone or with other medicines to find t…

This study tests whether adding the drug MK-2870 to standard pembrolizumab treatment helps people with advanced squamous non-small cell lung cancer live longer. About 851 participants will receive initial chemo plus pembrolizumab, then either continue pembrolizumab alone or add M…

This study tests the safety and effectiveness of combining two drugs, lorlatinib and ramucirumab, for people with advanced ALK-rearranged non-small cell lung cancer. About 56 adults will participate, starting with finding a dose that causes few side effects, then checking if the …

This study tests a new drug called HEC169096 in people with advanced solid tumors, including thyroid cancer and non-small cell lung cancer. The drug targets a specific genetic change (RET mutation or fusion) that helps the cancer grow. The study has two phases: first to find the …

This study is for people with advanced non-small cell lung cancer that does not have the PD-L1 protein. It compares two treatments: one using a single immunotherapy drug with chemotherapy, and another using two different immunotherapy drugs with chemotherapy. The goal is to see i…

This study looks at the best way to sequence EGFR-inhibitor drugs for people with advanced EGFR-mutated lung cancer that cannot be cured. About 200 participants will receive different orders of these targeted therapies, and researchers will track tumor response, side effects, and…

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…

This study tests a drug called pyrotinib as a first treatment for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene. About 18 adults will take the pill daily to see if it shrinks tumors and how safe it is. The goal is to control the cance…

This study tests whether adding a nitroglycerin patch to standard radiation therapy improves tumor control in the brain for people with advanced non-small cell lung cancer that has spread to the brain and has an EGFR mutation. About 74 participants will either get radiation alone…

This study tests a new drug (GEN-725) combined with dositinib in 110 adults with advanced EGFR-mutant non-small cell lung cancer that cannot be surgically removed. The goal is to see if the combination is safe and shrinks tumors or slows their growth. This is not a cure; it aims …

This study tests whether a new drug called telisotuzumab vedotin works better than a standard chemotherapy (docetaxel) for adults with a specific type of advanced non-small cell lung cancer that has a high level of a protein called c-Met. About 698 participants worldwide will be …

This study tests a drug called tarlatamab (AMG 757) given together with radiation therapy for cancers that have a protein called DLL3, such as certain lung cancers, melanomas, and brain tumors. The goal is to see if the combination is safe and helps shrink tumors. About 30 adults…

This study tests whether giving radiation to the main lung tumor before starting targeted therapy pills can delay cancer growth in people with advanced, gene-mutated non-small cell lung cancer. About 34 adults who have not yet had treatment will receive radiation to the primary l…

This study tests an experimental drug called SHR-1826 in about 90 adults with advanced or spreading non-small cell lung cancer who have already tried other treatments. Participants receive the drug by IV every three weeks. The main goal is to see if the drug shrinks tumors, while…

This study is for people with advanced non-small cell lung cancer whose previous treatment (PD-1/L1 therapy) stopped working. Researchers are testing a new combination of two drugs, ZG005 and gecacitinib, to see if it is safe and can shrink tumors. About 50 adults aged 18 to 75 w…

This study tests two experimental drugs, SI-B001 and SI-B003, with or without chemotherapy, in people with advanced non-small cell lung cancer. The first part finds a safe dose, and the second part checks if the treatment shrinks tumors. About 160 adults aged 18 to 75 are being r…

This study looks at whether adding surgery or radiation to the main tumor can help people with advanced EGFR-mutant lung cancer who have already responded to a combination of osimertinib and chemotherapy. About 70 adults will receive local therapy and be followed to see how long …

This study is testing whether combining an immunotherapy drug (atezolizumab) with an immune booster (BDB001) and targeted radiation can help control advanced solid tumors, including pancreatic, lung, bladder, and breast cancers. About 247 adults with these cancers will receive th…

This early-stage trial tests a new drug called MST-0312 in people with advanced solid tumors like lung, melanoma, bladder, colorectal, and triple-negative breast cancer. The drug is designed to activate a natural immune pathway to help the body fight cancer more effectively. It i…

This study tests whether adding the experimental drug MK-1084 to standard immunotherapy (durvalumab) can keep a certain type of advanced lung cancer from growing. The cancer must have a specific gene change called KRAS G12C and not have spread after initial chemotherapy and radia…

This early-phase study tests a new treatment for people with advanced lung cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The main goal is to check safety and fin…

This study tests whether a new experimental drug (PF-08634404) combined with chemotherapy works better than the current standard treatment (pembrolizumab plus chemotherapy) for adults with advanced non-small cell lung cancer. About 1,410 participants will be randomly assigned to …

This early-phase study tests an experimental drug called MGC026 in 250 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. Participants receive the drug by I…

This study tests whether lower doses of chemotherapy can effectively control lung cancer in patients aged 70+ or those with other health problems. About 280 participants will receive pre-set reduced chemo doses to see if tumors shrink while causing fewer side effects. The goal is…

This study tests whether combining a targeted pill (adagrasib) with precise radiation (SRS) can control brain tumors in people with a specific type of advanced lung cancer (KRAS G12C mutation). About 30 adults with untreated brain metastases will receive both treatments. The main…

This study tests two experimental drugs, BNT326 and BNT327, together in adults with advanced non-small cell lung cancer that has spread or come back. The goal is to find the best dose and see if the combination can shrink tumors and control the disease. About 420 participants wil…

This program provides early access to the investigational drug neladalkib for adults with advanced ALK-positive non-small cell lung cancer or other ALK-positive solid tumors who have run out of standard options and cannot join a clinical trial. Participants must have already trie…

This study tests whether adding a new drug (ivonescimab) to standard chemotherapy can help people with advanced non-small cell lung cancer who did well on initial immunotherapy but still have signs of cancer DNA in their blood. About 70 adults aged 18-75 will be randomly assigned…

This study tests whether giving the drug trastuzumab deruxtecan before routine surgery can shrink tumors in people with a specific type of lung cancer (HER2-amplified or HER2-mutated non-small cell lung cancer). About 14 adults with stage II to IIIB lung cancer will receive the d…

This program provides early access to the investigational drug zidesamtinib for adults with advanced ROS1-positive non-small cell lung cancer or other solid tumors who have run out of standard options and cannot join a clinical trial. Participants must have tried at least one pri…

This study tests an experimental oral drug called VMD-928, given alone or with pembrolizumab, in adults with advanced solid tumors or lymphoma that have stopped responding to standard treatments. The goal is to find safe doses and see if the drug can shrink tumors. About 242 peop…

This early-phase study tests an experimental drug called PRTH-101, alone or with the immunotherapy pembrolizumab, in adults with advanced or metastatic solid tumors (like lung cancer) that haven't responded to standard treatments. The main goals are to check the drug's safety, fi…

This study tests a new drug called LY4052031 in people with advanced or metastatic solid tumors, including bladder, breast, and lung cancers. The drug is designed to deliver a cancer-killing agent directly to tumor cells. The trial has two parts: first to find the safest dose, th…

This study tests an experimental drug called IDE034 in adults with advanced solid tumors that have not responded to standard treatments. The drug targets two markers (B7-H3 and PTK7) found on certain cancer cells. The main goals are to check safety, find the best dose, and see if…

This early-stage study is testing a new drug called BBO-8520 for people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The main goals are to check the drug's safety and see if it can shrink tumors. About 350 adults will take part, and the…

This study compares two treatments for people with advanced non-small cell lung cancer that has spread. One group gets a new drug called ivonescimab plus chemotherapy, and the other gets the standard drug pembrolizumab plus chemotherapy. The goal is to see which combination helps…

This early-phase study tests a new drug called PT0511 in adults with advanced solid tumors that have a KRAS mutation or amplification, including colorectal, pancreatic, and lung cancers. The main goals are to check safety, find the best dose, and see how the drug works alone or w…

This study tests a new drug, ASP5834, in people with advanced solid tumors that have specific changes in the KRAS gene. The goal is to find a safe dose and check for side effects. Some participants with colorectal cancer will also receive another drug, panitumumab. The study is f…

This study tests two drugs, envafolimab and lenvatinib, together in people with advanced solid tumors (lung, kidney, or liver cancer) that have stopped responding to standard treatments. The goal is to see if the combination can shrink tumors better than current options. About 17…

This study tests a new drug, AZD6750, that helps the immune system fight cancer. It is for adults with advanced solid tumors like melanoma, lung, or breast cancer that have not responded to other treatments. The goal is to find the safest dose and see if it shrinks tumors when us…

This study tests an experimental oral drug, S241656, in people with advanced cancers (like lung, colon, or pancreatic) that have certain gene changes (KRAS, BRAF, or related). The drug is taken daily in 28-day cycles, either alone or with other cancer treatments. The goal is to f…

This study tests whether a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy works better than the current standard (pembrolizumab plus chemotherapy) for people with advanced non-squamous non-small cell lung cancer whose tumors have PD-L1 lev…

This study tests a drug called zanidatamab in about 200 adults with several types of advanced solid tumors (like breast, lung, or stomach cancer) that have high levels of HER2 protein and have worsened after at least one prior treatment. The goal is to see if zanidatamab can shri…

This early-stage trial tests a treatment called GC101 TIL for people with advanced non-small cell lung cancer that has not responded to standard therapies. The treatment uses immune cells taken from the patient's own tumor, grown in a lab, and then given back to attack the cancer…

This study tests a new drug called andamertinib, given alone or with chemotherapy, for people with advanced non-squamous lung cancer that has certain rare EGFR mutations. The goal is to see if the drug can shrink tumors or slow the disease better than chemotherapy alone. About 40…

This study tests an investigational drug called telisotuzumab vedotin in about 150 adults with a specific type of advanced lung cancer (non-small cell lung cancer that has a marker called c-Met). Participants are randomly assigned to one of three different dose schedules of the d…

This study looks at people with early-stage non-small cell lung cancer who have finished standard treatment. A blood test checks for tiny bits of cancer DNA (ctDNA) that might mean the cancer could come back. If the test is positive, participants get a drug called durvalumab to t…

This study tests a new treatment for people with certain advanced cancers (like pancreatic, stomach, or colon cancer) that have a specific genetic change called KRAS G12V. The treatment involves taking a patient's own white blood cells, modifying them in a lab to better recognize…

This study tests whether using a protein-based test to guide treatment choices can help people with advanced non-small cell lung cancer live longer without their cancer getting worse. About 56 adults with stage IIIC or IV lung cancer will be randomly assigned to either standard t…

This study tests whether giving a low dose of radiation along with two immunotherapy drugs (ipilimumab and nivolumab) before surgery can shrink tumors in people with early-stage lung cancer. About 25 adults with resectable stage IB to III non-small cell lung cancer will receive t…

This study tests whether adding the immunotherapy drug envafolimab to standard chemotherapy helps people with stage III non-small cell lung cancer that can be surgically removed. About 390 participants will receive either envafolimab plus chemo or a placebo plus chemo before and …

This study tests a new drug called YL202 in about 100 people with advanced solid tumors, including lung, colorectal, and cervical cancers. The goal is to see if YL202 can shrink tumors and control the disease. Participants must be 18 or older and have a BMI between 18 and 32.

This program provides early access to the experimental drug zipalertinib for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion) and has worsened after standard chemotherapy. It is for those who have no other good treatment …

This study tests whether giving high-precision radiation (SBRT) to all visible cancer spots can delay the disease from getting worse in people with 1 to 5 metastases from breast or lung cancer. About 145 participants will either receive standard care alone or standard care plus S…

This early-stage study tests a new drug called CGT4255 in about 100 adults whose advanced solid tumors have certain genetic changes (ERBB2 alterations or HER2 overexpression). The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors, includi…

This study tests whether adding a new drug, BL-B01D1, to the standard pill osimertinib helps people with advanced EGFR-mutated non-small cell lung cancer live longer without their cancer growing. About 720 adults will be randomly assigned to get either the combination or osimerti…

This early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…

This study tests whether the immunotherapy drug cemiplimab can help prevent lung cancer from coming back after surgery. It is for people with stage II to IIIA non-small cell lung cancer whose tumors have a protein called PD-L1. Participants will receive cemiplimab infusions or be…

This study tests a new drug that delivers radiation directly to cancer cells in people with advanced solid tumors. The drug targets a protein found on cells that help tumors grow. The trial has two parts: first finding a safe dose, then testing if it works alone or with chemother…

This early-phase study tests a new oral drug called DO-2 in adults with advanced solid tumors (like lung or kidney cancer) that have not responded to standard treatments. The main goal is to check safety and find the right dose. About 55 people will take part, and researchers wil…

This study tests whether giving healthy donor fecal transplants (FMT) along with the immunotherapy drug pembrolizumab can help people with a certain type of advanced lung cancer (PD-L1 positive NSCLC) that has stopped responding to standard treatments. About 26 participants will …

This study tests a new drug combination (BL-B01D1 plus a PD-1 antibody) in 570 adults with advanced lung, nasopharyngeal, or other solid tumors that have spread. The main goals are to see if tumors shrink and to find the best dose. Participants must provide tumor samples and have…

This study tests whether adding the antidepressant olanzapine to standard immunotherapy helps people with advanced non-small cell lung cancer live longer. About 156 adults with a specific type of lung cancer (EGFR mutation-negative) will receive either immunotherapy alone or immu…

This study tests a new drug, firmonertinib, against two standard drugs (osimertinib or afatinib) in people with advanced lung cancer that has specific uncommon genetic changes (EGFR PACC mutations). About 480 participants who have not had prior treatment for advanced disease will…

This study tests whether combining two drugs, YL201 and ivonescimab, can safely shrink tumors in people with advanced solid cancers, including lung cancer. About 260 adults whose cancer has not responded to other treatments will receive the combination. The goal is to find the be…

This early-stage study tests a new radioactive drug, [177Lu]Lu-NNS309, in adults with advanced pancreatic, lung, breast, or colorectal cancers that have worsened after standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrin…

This study tests a combination of two drugs—tulmimetostat and pembrolizumab—in people with advanced non-small cell lung cancer whose cancer has gotten worse after standard treatments. The goal is to see if the combination can shrink tumors and control the disease. About 66 vetera…

This study tests a combination of three treatments (furmonertinib, chemotherapy into the spinal fluid, and precise radiation) as a first treatment for people with a specific type of lung cancer (EGFR mutation) that has spread to the brain and its lining. About 30 adults will take…

This study tests an experimental oral drug called 7HP349 (Alintegimod) taken with standard immunotherapy drugs (ipilimumab and nivolumab) for people with advanced solid tumors like melanoma, lung, kidney, or liver cancer who have already tried other treatments. The goal is to see…

This early-stage study tests a new drug called LY4050784 in people with advanced solid tumors that have a specific change in the SMARCA4 gene. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 340 participants will join, and…

This study compares a new drug called ivonescimab to the standard treatment pembrolizumab for people with advanced non-small cell lung cancer that has spread and shows high PD-L1 levels. About 780 adults with stage IV cancer will receive either drug as their first therapy. The go…

This study compares a new drug, HLX17, to the approved cancer drug Keytruda in 174 adults whose lung cancer, melanoma, or kidney cancer has been surgically removed. The goal is to see if HLX17 works similarly in the body and has similar safety and effectiveness. Participants will…

This study tests a new drug called LBL-024 combined with other medicines in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors or stop them from growing. About 230 adults aged 18-75 will take p…

This early-phase study tests a new type of proton beam surgery called HyPROS for people with early-stage non-small cell lung cancer. The goal is to see if a single, high-dose treatment is safe and can control the tumor. About 12 adults with good performance status will be enrolle…

This study tests an experimental drug called STX-721 in people with advanced non-small cell lung cancer that has specific changes in the EGFR or HER2 genes. The goal is to find a safe dose and see if the drug can shrink tumors. About 345 participants will take the drug by mouth, …

This study tests a new drug called Ivonescimab for people with non-small cell lung cancer who need surgery. The drug is given before surgery to shrink tumors and make them easier to remove. The study compares Ivonescimab to standard treatments and looks at how well it works and w…

This study tests whether combining two drugs, tepotinib and ivonescimab, is safe and works for people with advanced non-small cell lung cancer that has a specific genetic change called METex14 skipping. About 16 participants will try different doses to find the one with the fewes…

This study tests a new drug called YL202 combined with other anti-cancer treatments in people with advanced solid tumors, including breast and lung cancer. The goal is to see if the combination is safe and can shrink tumors. About 414 adults aged 18-75 who have already tried stan…

This study tests a drug called TolueneSulfonamide, injected directly into the chest, to safely reduce fluid buildup in people with lung cancer. About 105 adults with non-small cell lung cancer and trouble breathing will take part. The goal is to see if the drug can shrink the flu…

This study compares two treatments for early-stage non-small cell lung cancer in patients who are at high risk for standard surgery. One group gets a less invasive surgery (sublobar resection), and the other gets targeted radiation (SAbR). The goal is to see which approach helps …

This early-phase study tests whether adding a short course of high-dose radiation before standard chemotherapy and immunotherapy can help shrink borderline resectable non-small cell lung cancer before surgery. About 18 adults with stage II to IIIC lung cancer will receive three d…

This study tests a new medicine called PF-08634404 combined with other cancer drugs in people with advanced non-small cell lung cancer that has spread and cannot be removed by surgery. The goal is to see if the combination is safe, what side effects occur, and whether it can shri…

This study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors that have not responded to standard therapy. The main goals are to check safety and find the best dose. About 1,100 adults with various cancers like lung, st…

This early-stage study tests a new drug (tolododekin alfa) combined with an existing immunotherapy for people with advanced non-small cell lung cancer. The goal is to see if the combination can shrink tumors or slow disease progression. About 60 participants will join, including …

This early-phase trial tests a special immune cell therapy (CD40L TIL) combined with the drug nivolumab for people with advanced non-small cell lung cancer that has specific gene changes (EGFR, ALK, ROS1, or HER2). About 20 participants whose cancer worsened after standard treatm…

This study tests a combination of two drugs (HLX43 and serplulimab) given before surgery to people with non-small cell lung cancer. The goal is to see if this treatment can shrink tumors and improve outcomes. About 60 adults with stage II-IIIB lung cancer will participate.

This study tests a new drug, iruplinalkib, in 20 adults with advanced ALK-positive lung cancer that has worsened after or caused side effects from lorlatinib. Researchers will track how long the drug controls the cancer and monitor safety in real-world settings. The goal is to pr…

This study tests whether adding a traditional Chinese herbal decoction (HGXJT) to standard immunotherapy can help control lung cancer that has spread to the bones. About 82 adults with a specific type of lung cancer (non-small cell, without certain gene mutations) will receive ei…

This early-stage study tests a new drug called OCT-598 in people with advanced solid tumors (such as breast, lung, or prostate cancer) that have not responded to other treatments. The main goal is to find a safe dose and check for side effects when given alone or with standard ca…

This study tests whether adding radiotherapy to immunotherapy after surgery can help people with a certain type of advanced lung cancer (stage III N2 non-small cell lung cancer) live longer without the cancer coming back. About 60 adults aged 18 to 75 who have had surgery and hav…

This study tests a new drug called TUB-040 in people with ovarian cancer that no longer responds to platinum chemotherapy, or with a type of lung cancer that has come back. TUB-040 is designed to deliver a cancer-killing agent directly to tumor cells that have a specific marker (…

This study looks at whether adding electroacupuncture (a type of acupuncture with mild electric pulses) to standard immunotherapy can help people with advanced non-small cell lung cancer who are too weak for aggressive treatment. About 120 participants will receive either real or…

This study tests a drug called divarasib, either alone or with other cancer treatments, in people with advanced lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the drug is safe and works to shrink or control the cancer. About 320 people who have …

This study is for people with advanced non-small cell lung cancer who are not well enough for standard strong chemotherapy. It tests a combination of one chemotherapy drug and an immunotherapy drug (pembrolizumab) to see if it is safe and helps shrink tumors. About 60 participant…

This study is testing a precise, high-dose radiation treatment called SBRT for people with non-small cell lung cancer or cancer that has spread to the lungs. About 200 participants will receive 3 to 10 radiation sessions over 1-2 weeks. The goal is to see how well the treatment c…

This study tests whether adding targeted radiation to liver tumors can make standard immunotherapy work better for people with advanced non-small cell lung cancer (NSCLC) that has spread to the liver. About 68 adults with stage IV NSCLC will receive either standard drug therapy a…

This early-phase study tests a new drug called BL-M24D1 in 33 adults with advanced non-small cell lung cancer or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried standard…

This study tests an experimental drug called TNG260 combined with an immunotherapy (pembrolizumab) in people with advanced solid tumors that have a specific gene change (STK11 mutation). The goal is to find the best dose and see if the combination is safe and can shrink tumors. A…

This study tests whether combining an immunotherapy drug (toripalimab) with a cold-based tumor destruction technique (cryoablation) can help control advanced non-small cell lung cancer that has started to grow again after initial treatment. About 54 adults with limited new tumor …

This study tests whether removing extra safety margins during adaptive radiation therapy can lower lung side effects while still controlling tumors. About 130 adults with early-stage non-small cell lung cancer or limited lung metastases will receive either standard or margin-free…

This study is for veterans with stage 3 non-small cell lung cancer that cannot be removed by surgery. It combines chemotherapy, immunotherapy, and radiation to see if this approach helps control the cancer longer and is safe. About 25 participants will receive the treatment, and …

This study tests whether removing extra safety margins during MRI-guided radiation can safely treat lung cancer that has spread to the brain. About 168 adults with 1 to 10 brain metastases will receive precise, adaptive radiation without the usual buffer zone. The goal is to redu…

This study tests a new drug called SHR-A2102 combined with other cancer treatments for people with a type of lung cancer that can be removed by surgery. The goal is to see if the combination can destroy more cancer cells before and after the operation, helping patients live longe…

This study tests a new experimental drug called SIM0610 in adults with advanced solid tumors that have spread. The main goals are to check the drug's safety and find the right dose. About 260 people with cancers like lung, colorectal, head and neck, or liver cancer will take part…

This early-phase study tests a new oral drug, PF-07799933, in people aged 16 and older with advanced solid tumors (like melanoma, lung, or colon cancer) that have a specific BRAF gene change and have stopped responding to standard treatments. The drug is given alone or combined w…

This study tests a new oral drug, RMC-6236, against standard chemotherapy (docetaxel) in about 590 adults with advanced non-small cell lung cancer that has a specific RAS mutation and has already been treated with immunotherapy and platinum chemo. The goal is to see if the new dr…

This study tests a drug called zanidatamab in people with certain advanced cancers (lung, endometrial, colorectal, head & neck, or sarcoma) that have a specific gene change (HER2). The goal is to see if the drug can shrink tumors. Participants receive the drug by IV every 3 weeks…

This study tests a new radioactive drug (177Lu-DFC413) to see if it is safe and how it works in people with advanced solid tumors, including pancreatic, lung, breast, colorectal cancers, and soft tissue sarcoma. About 180 adults will receive the drug, and researchers will monitor…

This early-stage study tests a new treatment using a patient's own immune cells, modified in a lab to recognize and attack cancer cells with a specific KRAS mutation. It is for adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to s…

This study is for people with a type of lung cancer that has spread to only a few places in the body and has a specific gene change. Participants will either continue taking their targeted therapy pills alone or also receive radiation to the cancer spots. The goal is to see if ad…

This study tests a new drug called ANS02 in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). The goal is to see if the drug is safe, how the body processes it, and whether it can shrink tumors. About 294 adults will take part in …

This study compares two types of minimally invasive lung surgery for people with early-stage non-small cell lung cancer: robot-assisted surgery (RATS) and video-assisted surgery (VATS). About 1,124 participants will be randomly assigned to one of the two procedures. The main goal…

This early-phase study tests a new drug that delivers radiation directly to cancer cells. It is for people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to other treatments. The main goals are to check safety and find the best dose. A…

This study tests whether a special type of radiation (SFRT) combined with the immunotherapy drug tislelizumab and standard chemotherapy can shrink stage III non-small cell lung cancer enough to allow surgery. About 30 adults whose cancer was initially too advanced to operate will…

This study tests a new combination of two drugs, DZD6008 and sunvozertinib, in people with advanced non-small cell lung cancer that has specific EGFR mutations. The goal is to see if the combination is safe and can shrink or control tumors. About 160 adults will take part in this…

This early-stage trial tests whether adding Tumor Treating Fields (TTFields) to standard chemoradiation and immunotherapy is safe for people with stage III non-small cell lung cancer that cannot be removed by surgery. About 30 participants will receive TTFields alongside their us…

This study tests a new combination of two drugs (trastuzumab deruxtecan and pembrolizumab) against standard chemotherapy plus pembrolizumab as a first treatment for people with advanced non-small cell lung cancer that has high levels of HER2 and low PD-L1. About 686 adults will t…

This study tests several new drug combinations in people with advanced non-small cell lung cancer that has spread. The goal is to see if these combinations are safe and can shrink tumors. About 278 adults will take part across 10 countries. The study is open to those with a speci…

This early-phase study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific genetic mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). The treatment uses a patient's own immune cells, whi…

This study tests a new oral drug, sutetinib maleate, in people with advanced non-small cell lung cancer that has uncommon EGFR mutations. The goal is to see if the drug can shrink tumors or slow cancer growth. About 66 adults will take the capsule and be monitored for response an…

This study tests a new experimental drug called mavrostobart (PT199) in people with advanced solid tumors, specifically non-small cell lung cancer and pancreatic cancer. The drug is given alone or combined with other cancer treatments. The goal is to find the safest dose and see …

This study looks at how well the drug pembrolizumab (with or without chemotherapy) works in Black patients with advanced non-small cell lung cancer. About 318 people will join, and researchers will track survival and tumor response. The goal is to find out which patients benefit …

This study tests whether a combination of two experimental drugs (IN10018 and D-1553) works better than the usual treatment for people with a specific type of advanced lung cancer called KRAS G12C non-small cell lung cancer. About 400 adults who have not had prior treatment for t…

This study tests whether adding a new drug (Dato-DXd) to the standard pill osimertinib can help people with advanced EGFR-mutant lung cancer live longer without their cancer growing. About 582 adults with stage IIIB/IV non-small cell lung cancer will receive either the combinatio…

This study tests a new drug, WSD0922-FU, in 40 adults with advanced non-small cell lung cancer that has a specific genetic change (C797S mutation) and has stopped responding to the standard first treatment, osimertinib. The goal is to see if the drug can shrink tumors or slow the…

This phase 3 trial tests whether using MRI scans to guide radiation therapy can reduce lung side effects and improve outcomes for people with locally advanced non-small cell lung cancer. About 490 participants will receive radiation, chemotherapy, and immunotherapy, with half get…

This study tests whether adding the experimental drug SHR-A2009 to the standard pill aumolertinib works better than aumolertinib alone for people with advanced non-small cell lung cancer that has an EGFR mutation. About 576 adults who have not had prior treatment will be randomly…

This study tests whether adding a surgical sealant called Progel Platinum to standard stapling during lung cancer surgery can reduce the time patients need a chest tube. About 160 adults having minimally invasive lung lobe removal for non-small cell lung cancer will take part. Th…

This study tests whether adding high-dose radiation to standard drug therapy helps people with non-small cell lung cancer that has spread to up to 5 spots live longer. About 240 participants will receive either standard treatment alone or standard treatment plus radiation to all …

This study tests a new drug called CKD-703 for people with advanced solid tumors or a type of lung cancer (non-small cell lung cancer) that has not responded to standard treatments. The drug is designed to seek out and attack cancer cells that have a specific marker (c-Met) while…

This early-phase trial tests a personalized cell therapy for people with several types of advanced cancer that have spread and express a specific marker called NY-ESO-1. Participants receive a single infusion of their own immune cells that have been genetically modified to recogn…

This study tests a new treatment using a patient's own immune cells (called TILs) to prevent non-small cell lung cancer from returning after surgery. About 45 adults who have already had chemotherapy and surgery will be randomly assigned to receive either TILs plus standard care,…

This study tests a new approach for people with advanced lung cancer whose disease got worse after standard first-line treatment. Participants receive an experimental virus (Olvi-Vec) followed by chemotherapy plus an immunotherapy drug, or the standard chemotherapy docetaxel alon…

This study tests whether a lower dose of the targeted therapy osimertinib can control advanced EGFR-positive non-small cell lung cancer while reducing side effects. About 58 adults with this specific genetic type of lung cancer will receive 80 mg every other day. Researchers will…

This study compares two treatments for people with advanced squamous non-small cell lung cancer who have not had prior therapy. Participants will receive either the experimental drug RC148 or the approved drug tislelizumab, both combined with chemotherapy. The goal is to see whic…

This study tests a new approach for people with stage II to III non-small cell lung cancer that can be surgically removed. Before surgery, patients receive low-dose radiation plus focused high-dose radiation, followed by a combination of an immunotherapy drug (tislelizumab) and s…

This early-stage trial tests an experimental drug called HMBD-501 in 180 adults with advanced solid tumors (melanoma, lung, or breast cancer) that have come back or not responded to standard therapies. The drug targets a protein called HER3 found on cancer cells. The study has tw…

This study tests whether combining three anti-cancer drugs (carboplatin, paclitaxel, and ramucirumab) can shrink tumors or slow their growth in people with advanced non-small cell lung cancer that has progressed after initial treatment. About 59 adults with stage IV or recurrent …

This study tests two experimental drugs, SI-B003 and BL-B01D1, alone or together, in people with advanced lung cancer or nasopharyngeal cancer that has spread. About 121 adults aged 18 to 75 will take part to see if the combination shrinks tumors and to find the best dose. The go…

This study tests whether adding low-dose radiation to the liver can help immunotherapy work better for people with melanoma or non-small cell lung cancer that has spread to the liver. About 21 participants will receive standard immunotherapy plus targeted liver radiation. The goa…

This study tests a new daily pill, VS-7375, in people with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific KRAS G12D mutation. The goal is to see if the drug is safe and can shrink tumors when used alone or with other cancer treatments. Ab…

This early-stage study tests a new mRNA-based treatment called BNT116 for people with advanced non-small cell lung cancer. The goal is to find safe doses when given alone or with other cancer drugs. About 320 participants with different stages of lung cancer will take part. The s…

This study is for people with early-stage non-small cell lung cancer (stages IB to IIIB) that can be removed by surgery. Researchers are testing several targeted drugs based on the tumor's genetic markers, given before and after surgery. The goal is to see if these treatments can…

This study tests whether adding the targeted drug MK-1084 to standard immunotherapy (pembrolizumab) after surgery can prevent lung cancer from coming back in people with a specific KRAS mutation. About 400 adults with stage IIA-IIIB non-small cell lung cancer that has been fully …

This study tests whether adding AGuIX nanoparticles to precise, MRI-guided radiation can better control centrally located lung tumors and advanced pancreatic cancer. About 100 adults with these cancers will receive the combination therapy. The goal is to find the safest dose and …

This study tests whether adding a third cancer drug to the standard immunotherapy (cemiplimab) and chemotherapy helps shrink early-stage lung cancer more before surgery. About 120 adults with stage II-IIIB non-small cell lung cancer will receive either the standard two-drug combo…

This early-phase study tests a vaccine that targets specific KRAS mutations in advanced non-small cell lung cancer. About 12 participants will receive the vaccine alongside standard chemotherapy and two immunotherapy drugs (nivolumab and ipilimumab). The main goal is to check saf…

This early-phase study tests a new drug that delivers radiation directly to cancer cells by targeting a protein called Nectin-4. It is for people with advanced solid tumors (like bladder, breast, lung, or cervical cancer) that have not responded to prior treatments. The main goal…

This study tests a new drug, BNT327, combined with chemotherapy and other agents in people with advanced non-small cell lung cancer who have not had prior treatment. The trial will enroll about 1,260 participants across multiple sites worldwide. The goal is to see if the combinat…

This program provides the experimental drug ulixertinib to people with advanced solid tumors that have certain gene mutations (MAPK pathway). It is for patients who have not responded well to or have run out of standard treatments. The goal is to control the disease and possibly …

This study tests whether adding a special type of radiation (SFRT) to standard cancer treatment can help control non-small cell lung cancer that has started to grow again after initial therapy. About 25 adults whose cancer has progressed in a limited number of spots will receive …

This study tests an experimental drug called GV20-0251 in adults with advanced solid tumors (like lung, head and neck, or colon cancer) that no longer respond to approved therapies. The goal is to see if the drug can shrink or control the tumors. About 350 participants will take …

This study looks at whether giving radiation to the chest after surgery and chemo-immunotherapy can help people with stage III non-small cell lung cancer who still have signs of cancer after treatment. About 118 adults will be randomly assigned to receive or not receive radiation…

This study tests an experimental drug called CP-383 in 150 people with advanced solid tumors (like lung, colon, or pancreatic cancer) that haven't responded to standard treatments. Participants take the drug daily to see if it slows cancer growth and to find the best dose. The go…

This study tests several new drug combinations given before and after surgery for people with early-stage non-small cell lung cancer. The goal is to see if these combinations can destroy more cancer cells and prevent the cancer from coming back. About 630 adults with stage II to …

This study tests whether adding a second immunotherapy drug (domvanalimab) to the standard drug durvalumab can better control stage III lung cancer that hasn't grown after initial chemo-radiation. About 860 adults with a specific type of lung cancer will receive either the combo …

This study tests whether a new drug (divarasib) combined with immunotherapy (pembrolizumab) works better than standard chemotherapy plus immunotherapy for people with a specific genetic mutation (KRAS G12C) in advanced non-small cell lung cancer. About 600 adults who have not had…

This study tests a treatment that uses immune cells taken from a patient's own lung tumor. These cells are grown in large numbers and given back to the patient to attack the cancer. The trial includes 30 adults with advanced non-small cell lung cancer that has worsened after stan…

This study tests a drug called DRP-104 in people with advanced non-small cell lung cancer that has specific gene changes (NFE2L2 or KEAP1). The drug works by blocking glutamine, a nutrient cancer cells need to grow. The trial aims to see if the drug can shrink tumors or slow the …

This study looks at whether a simple blood test can find tiny bits of cancer DNA left in the body after lung cancer surgery. People whose blood shows these cancer signals will get extra treatment (chemotherapy and immunotherapy) to try to stop the cancer from coming back. The goa…

This study tests a new medicine, PF-08634404, given alone or with chemotherapy for adults with early or locally advanced non-small cell lung cancer. The goal is to see if it can shrink tumors before surgery or prevent cancer from returning after treatment. About 120 participants …

This study tests an experimental pill called WJ22096 in about 20 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) who have run out of standard options. The goal is to find a safe dose and see if the drug can shrink tumors. Participants take the pill by m…

This study tests a combination of three drugs (datopotamab deruxtecan, carboplatin, and pembrolizumab) in people with non-small cell lung cancer that has spread to the brain and has not been treated yet. About 46 adults will receive the drugs every three weeks for four cycles, th…

This study compares a new drug, NVL-655, to the current standard alectinib in people with advanced ALK-positive non-small cell lung cancer who have not had prior treatment. The goal is to see if NVL-655 can keep the cancer from growing longer. About 450 participants will be rando…

This study tests a new treatment using a patient's own immune cells, called CAR T cells, that are specially designed to target and kill solid tumor cells while leaving healthy cells unharmed. It is for adults with certain advanced cancers, including lung, colon, pancreatic, ovari…

This study tests a new oral drug, TNG456, in people with advanced solid tumors that lack the MTAP gene. The drug aims to slow or shrink tumors by blocking a protein these cancers rely on. Up to 191 adults will receive TNG456 alone or with another drug (abemaciclib) to find the sa…

This study tests a new drug called nelmastobart combined with the chemotherapy docetaxel in people with advanced non-small cell lung cancer that no longer responds to platinum chemo or immunotherapy. About 62 participants will receive the combination to see if it slows cancer gro…

This study tests a new drug, Rina-S, in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if Rina-S is safe and how well it works against cancers like ovarian, lung, and breast cancer. About 884 participants will receive the dru…

This study tests whether adding an experimental mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can better prevent lung cancer from coming back after surgery. About 868 adults with stage II-IIIB non-small cell lung cancer who have had their tumor completely removed …

This study tests a new drug called BLU-924 in people with advanced pancreatic, lung, or colorectal cancer that has a specific KRAS mutation. The drug aims to block the mutated protein and slow or shrink the cancer. The trial will check safety, side effects, and how well the drug …

This study tests a new drug called pumitamig combined with standard chemotherapy for people with advanced non-small cell lung cancer that has worsened after initial treatment. About 60 participants will receive the combination to see if it is safe and helps shrink tumors. The goa…

This study tests a daily pill called sunvozertinib against a placebo in 360 people with a specific type of lung cancer (stage IB-IIIA) who have had surgery to remove their tumor. The goal is to see if the drug can stop the cancer from returning. Participants must have certain EGF…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help people with stage III non-small cell lung cancer. After three cycles of the combination, a team decides if the patient can have surgery. Those who have surgery get more atezolizu…

This early-stage study tests a new drug called azirkitug, alone or with other cancer medicines, in people with advanced solid tumors like lung, head/neck, and pancreatic cancers. The goal is to find safe doses and check side effects. About 694 adults will take part worldwide, rec…

This early-stage study tests a new drug called AOH1996 in adults with solid tumors that have stopped responding to standard treatments. The main goal is to find the safest dose and check for side effects. About 92 people with cancers like lung, ovarian, or pancreatic cancer will …

This study tests the safety of a new drug called ivonescimab when given with standard chemotherapy and targeted radiation (SRS) for people with non-small cell lung cancer that has spread to the brain. Researchers will find the best dose with the fewest side effects, then test it …

This study tests whether adding the drug MK-2870 to pembrolizumab after surgery helps prevent lung cancer from coming back. It is for people with stage II to IIIB non-small cell lung cancer whose cancer did not fully disappear after chemotherapy and pembrolizumab before surgery. …

This early-stage trial tests an experimental drug called MRTX1719 in adults with advanced solid tumors that have a specific missing gene (MTAP deletion). The study includes people with cancers like mesothelioma, lung cancer, and pancreatic cancer that cannot be removed by surgery…

This phase 3 study tests whether adding metformin (a common diabetes medicine) to standard targeted therapy (tyrosine kinase inhibitors) can help people with advanced non-small cell lung cancer that has an EGFR mutation. About 312 participants will receive either metformin or a p…

This study looks at whether adding a precise type of radiation called stereotactic radiosurgery (SRS) to standard drug therapy can better control brain tumors in people with melanoma or non-small cell lung cancer that has spread to the brain. About 180 participants with newly dia…

This study is for people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) whose cancer has spread to other parts of the body after they finished treatment with the drug osimertinib. The trial will give these patients a combination of osimertinib and ch…

This study tests whether a new targeted pill (calderasib) plus an immunotherapy drug can help people with a specific type of advanced lung cancer (KRAS G12C mutation) live longer without their cancer growing. About 675 adults with non-squamous non-small cell lung cancer that has …

This study tests whether giving a precise, high-dose radiation treatment (SBRT) before chemotherapy can better control stage III non-small cell lung cancer. It involves 20 adults aged 18-75 with tumors smaller than 6 cm. The goal is to see if this combination improves local tumor…

This study tests a combination of a healthy gut bacteria (EXL01) and the immunotherapy drug nivolumab for people with advanced non-small cell lung cancer that no longer responds to standard treatments. The goal is to see if adding the bacteria can help the immune system fight the…

This study tests a new drug called sunvozertinib combined with chemotherapy in people with advanced non-small cell lung cancer that has specific EGFR mutations. Participants must have already tried and failed an EGFR-targeted therapy. The goal is to see if the combination can shr…

This early-phase study tests a new drug called EPI-326 in about 110 people with advanced lung cancer (with a specific EGFR gene change) or head/neck cancer. The main goal is to find a safe dose and check for side effects. Researchers will also see if the drug helps shrink tumors.

This study tests an experimental drug called telisotuzumab adizutecan in people with a specific type of advanced lung cancer (EGFR-mutated non-squamous non-small cell lung cancer) that has gotten worse after standard targeted therapy. About 430 adults will receive either the new …

This study tests a new drug called volrustomig combined with other cancer medicines in people with non-small cell lung cancer. The goal is to see if the combination is safe and can shrink tumors. About 180 adults with advanced lung cancer will take part.

This study is for adults with certain cancers (like breast, lung, or ovarian) that are in complete remission but have persistently low platelet counts from past chemotherapy. It tests whether adding a vitamin A derivative (ATRA) to a standard platelet-boosting drug works better t…

This study is for people with a type of advanced lung cancer (non-small cell) that cannot be treated with surgery or standard chemo-radiation. It tests adding experimental drugs that block DNA repair to standard radiation therapy, followed by a year of immunotherapy (durvalumab).…

This study tests whether the drug anlotinib can help prevent lung cancer from returning in patients who still had cancer cells after surgery and chemotherapy. About 64 adults with stage IIA-IIIA non-small cell lung cancer will take anlotinib capsules. The main goal is to see how …

This study is for people with a specific type of lung cancer (EGFR-mutated) that can be removed with surgery. It tests whether giving a new drug, sacituzumab tirumotecan, alone or with another drug (osimertinib) before surgery can shrink the tumor more effectively. About 60 adult…

This early-stage study tests a new drug called IBI3028 in about 493 adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. It is an open-label study, meaning …

This study offers continued treatment with the drug adagrasib to cancer patients who have already been benefiting from it in earlier studies. It is for people with advanced solid tumors like lung or colorectal cancer. The main goal is to monitor safety and side effects over the l…

This early-phase study tests a new drug called DR-0202 in people with advanced solid tumors (like breast, lung, or prostate cancer) that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the right dose. About 96 participants…

This study tests two experimental drugs, DZD9008 and AZD4205, together in people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation) and has stopped responding to standard treatments. About 90 adults will take part to see if the combination is…

This study tests whether a new combination of two experimental drugs (livmoniplimab and budigalimab) plus chemotherapy works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-squamous non-small cell lung cancer that has spre…

This phase 2 trial tests TQB2102, a drug that delivers a powerful toxin directly to cancer cells with a specific genetic change (HER2 abnormality). The study aims to see if the drug can shrink tumors in 270 adults with advanced non-small cell lung cancer that cannot be removed by…

This study tests a new drug called gotistobart (ONC-392) against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that worsened after prior immunotherapy. About 630 adults will receive either the new drug or chemotherapy every 3 weeks for up to…

This study tests whether higher doses of the targeted therapy furmonertinib, alone or with chemotherapy, can control advanced non-small cell lung cancer in people whose cancer worsened after initial treatment. About 60 participants will be randomly assigned to one of three treatm…

This early-stage study tests a new drug called 177Lu-RAD204, which is a radioactive antibody designed to seek out and attack cancer cells. About 30 adults with advanced solid tumors (like lung, breast, or skin cancer) that have not responded to other treatments will receive the d…

This study tests a new surgical technique called septum-guided segmentectomy for people with small, early-stage lung cancer located deep in the lung. The goal is to remove the cancer completely while saving as much healthy lung tissue as possible, which may help preserve breathin…

This study is for people with early-stage non-small cell lung cancer that can be removed with surgery. Researchers want to see if adding an inhaled form of the drug azacytidine to standard chemotherapy and immunotherapy can help kill more cancer cells before surgery. The trial wi…

This study tests the drug fingolimod (currently used for multiple sclerosis) in 38 adults with advanced non-small cell or small cell lung cancer that worsened after standard treatments. Participants take one pill daily to see if it can slow tumor growth and improve survival. The …

This study tests a new cancer medicine (PF-07799544) taken as a pill, alone or with another drug, in adults with advanced solid tumors that have a specific gene change (BRAF V600). The goal is to see if the combination is safe and can shrink or control tumors. About 124 people wi…

This early-phase study tests a new experimental treatment called VET3-TGI, a virus designed to attack cancer cells. It is given alone or with another drug (atezolizumab) to about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals a…

This phase 3 trial tests whether adding the immunotherapy drug durvalumab after surgery and initial chemo-immunotherapy can help prevent lung cancer from coming back in people with stage IIB-IIIB non-small cell lung cancer. About 290 participants will receive either durvalumab fo…

This study tests whether adding valemetostat to the standard immunotherapy pembrolizumab helps control advanced non-small cell lung cancer better than pembrolizumab alone. About 137 adults with high PD-L1 levels and no targetable gene changes will participate. The goal is to see …

This early-phase study tests a new drug called BBO-11818 in people with advanced cancers that have a KRAS mutation, including lung, pancreatic, and colorectal cancers. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. Abou…

This study tests whether a personalized cancer vaccine (intismeran) given alone or with an immunotherapy drug (pembrolizumab) can prevent high-risk stage I non-small cell lung cancer from returning after complete surgical removal. About 876 adults whose tumors have certain high-r…

This study tests a new pill called dositinib for people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation). The goal is to find a safe dose and see if it shrinks tumors. About 153 adults aged 18-75 who have tried other treatments without succ…

This study tests whether adding BIO 300 to standard chest radiation can prevent severe lung inflammation (pneumonitis) in people with early-stage non-small cell lung cancer who also have interstitial lung disease (scarred lungs). About 25 participants will receive the drug alongs…

This study tests a new drug called MCLA-129 in people with advanced solid tumors, including lung, head and neck, and colorectal cancers that have not responded to standard treatments. The drug is a bispecific antibody designed to attach to two cancer-related proteins (EGFR and c-…

This study tests whether the drug ivonescimab, given after standard radiation therapy (SBRT), can help prevent early-stage non-small cell lung cancer from returning. About 36 people with tumors up to 7 cm will receive the drug as a consolidation treatment. The main goal is to see…

This early-stage study tests a new drug, tolododekin alfa (ANK-101), injected directly into tumors. It is for people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the best dose, both when used alone and with…

This study tests a combination of two drugs, HLX43 and Serplulimab, in people with advanced or metastatic solid tumors (including non-small cell lung cancer) who have not responded to standard treatments. The goal is to find the safest dose and see if the drugs can shrink tumors.…

This study tests a new treatment for people with advanced non-small cell lung cancer that has not responded to standard therapies. Participants receive a single infusion of specially engineered natural killer (NK) cells designed to recognize and attack tumors that have two specif…

This study tests whether adding a short course of a MEK inhibitor (mirdametinib) to standard chemoimmunotherapy is safe and effective for people with advanced non-squamous non-small cell lung cancer that has low PDL1 levels. The trial has two parts: first finding the best dose, t…

This early-phase study tests a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. About 101 people with certain cancer…

This study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…

This study is testing a new drug (QL1706) combined with chemotherapy for people with a certain type of lung cancer that can be removed with surgery. The goal is to see if giving the drugs before and after surgery helps shrink the tumor and prevent the cancer from coming back. Abo…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 470 adults will take part.

This study tests whether a daily pill called zongertinib can help prevent lung cancer from coming back in people with early-stage (Stage II-IIIB) non-small cell lung cancer that has a specific HER2 mutation. All participants have had surgery to remove their tumor and standard che…

This study tests a new drug, SKB264, combined with an immunotherapy drug (KL-A167) with or without chemotherapy in 110 adults with advanced or metastatic non-small cell lung cancer. The goal is to see if the combination is safe and can shrink tumors. Participants must have a spec…

This study tests whether adding new drugs, like patritumab deruxtecan, to standard immunotherapy (pembrolizumab) with or without chemotherapy can better treat advanced non-small cell lung cancer that has spread. About 90 people with untreated stage IV NSCLC will participate. The …

This study tests an experimental treatment called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has spread or stopped responding to standard therapy. OBX-115 uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are modified in the…

This study tests the drug cabozantinib in people with advanced non-small cell lung cancer whose tumors have certain gene changes (RET, ROS1, NTRK fusions or increased MET/AXL activity). The drug is taken by mouth and aims to shrink tumors and stop them from growing. About 86 part…

This study tests a drug called lazertinib, given alone or with chemotherapy, before surgery for people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer). The goal is to see if the treatment shrinks tumors enough to improve surgery outcomes. About 160 a…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The goal is to see if the drug is safe and shrinks tumors. About 300 adults whose cancer has worsened after prior treatment …

This study tests whether adding the experimental drug MK-1084 to standard immunotherapy (pembrolizumab) helps people with a specific genetic form of advanced lung cancer (KRAS G12C mutation) live longer without their cancer growing. About 600 adults with newly diagnosed, advanced…

This study tests an experimental drug called STK-012, alone or with standard chemotherapy and immunotherapy, in people with advanced solid tumors and untreated non-small cell lung cancer. The goal is to find the safest dose and see if adding STK-012 improves tumor shrinkage. Abou…

This study is for people with advanced EGFR-mutated non-small cell lung cancer whose cancer still shows signs of activity (detected by a blood test) after taking the drug osimertinib alone. The trial will test whether adding a second drug, sacituzumab tirumotecan, can improve out…

This early-phase study tests a new drug, LY3962673, in people with advanced solid tumors that have a specific KRAS G12D mutation, including pancreatic, lung, and colorectal cancers. The main goals are to check safety and see if the drug shrinks tumors, given alone or with chemoth…

This study tests whether a new drug combination (datopotamab deruxtecan plus rilvegostomig) or rilvegostomig alone works better than the current standard treatment (pembrolizumab) for people with advanced non-squamous lung cancer that has high PD-L1 levels. About 675 participants…

This study tests whether a focused ultrasound device can safely open the blood-brain barrier in people with non-small cell lung cancer that has spread to the brain. About 30 participants will receive standard immunotherapy plus the ultrasound procedure. The goal is to see if this…

This study is for people with stage III non-small cell lung cancer that cannot be removed by surgery. Researchers want to see if adding another immunotherapy drug (tremelimumab) and extra chemotherapy to the standard drug (durvalumab) can lower the amount of cancer DNA found in t…

This early-stage trial tests a new drug called OKN4395, alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The study aims to find the safest dose and check for early signs of tumor shrinkage. A…

This study tests a daily pill called sunvozertinib in 34 people with advanced non-small cell lung cancer that has rare EGFR gene mutations. Participants have not had prior cancer treatment. The goal is to see if the drug shrinks tumors and delays cancer growth. This is a phase 2 …

This study tests whether adding targeted radiotherapy to usual drug therapy can slow the growth or spread of metastatic non-small-cell lung cancer. About 320 adults whose cancer has started to grow in a few spots while on first-line treatment will receive either standard drugs al…

This early-stage study tests a new drug called DZD6008 in people with advanced non-small cell lung cancer that has certain EGFR gene mutations. The main goals are to check the drug's safety and see if it can shrink tumors. About 140 adults will take part in this open-label study …

This early-phase study tests an experimental drug called LNCB74 in people with advanced solid tumors (cancers that have spread and are hard to treat), including ovarian, breast, endometrial, bile duct, and lung cancers. The main goals are to find a safe dose and see if the drug s…

This study tests whether adding SKB264 to the standard drug osimertinib helps people with a specific type of advanced lung cancer (EGFR-mutated non-squamous non-small cell) live longer without their cancer growing. About 420 adults who have not had prior treatment for advanced di…

This early-phase study tests a new treatment called PeptiCRAd-1, a virus that carries cancer-targeting signals, combined with the immunotherapy drug pembrolizumab. About 15 adults with certain advanced cancers (like melanoma, lung, or breast cancer) will receive the combination t…

This study tests a new drug called FMC-376 in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the drug is safe and shrinks tumors. About 403 adults with lung, colorectal, or pancreatic cancer that has spread or cannot …

This early-stage study tests a new cancer treatment called FT836, a type of immune cell that is made in a lab and ready to use (off-the-shelf). It is given to people with advanced solid tumors like lung, colorectal, breast, ovarian, endometrial, or head and neck cancers that have…

This study tests a new drug (ES102) combined with an immunotherapy (toripalimab) in 40 adults with advanced non-small cell lung cancer that has not responded to prior treatments. The goal is to see if the combination can shrink tumors and control the disease. Participants must no…

This early-phase study tests whether adding carotuximab to the standard drug osimertinib is safe and tolerable for people with advanced EGFR-mutated non-small cell lung cancer. About 60 adults whose cancer has worsened after prior treatments will take part. The main goal is to fi…

This study tests a new drug called rilvegostomig combined with chemotherapy as a first treatment for people with advanced squamous non-small cell lung cancer that has spread. About 880 participants will be randomly assigned to receive either rilvegostomig or the standard drug pem…

This early-phase study tests a new drug called GNC-077, a multi-specific antibody injection, in about 20 people with advanced non-small cell lung cancer or other solid tumors that have spread. The main goals are to check the drug's safety, find the right dose, and see early signs…

This study tests whether adding the experimental drug SKB264 to the immunotherapy pembrolizumab works better than standard chemotherapy plus pembrolizumab for people with advanced non-squamous lung cancer that lacks the PD-L1 protein. About 432 adults with stage IIIB/IV disease w…

This early-stage study tests a new drug called CTX-8371 in people with advanced cancers that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 85 adults with certain types of lung, breast, lymphoma, head and neck,…

This study tests whether adding the targeted drug vebreltinib to standard chemotherapy helps people with advanced MET-positive non-squamous lung cancer live longer without their cancer growing. About 300 adults who have not had prior treatment for their advanced cancer will be ra…

This study is testing a blood test that looks for tumor DNA to see if it can more accurately tell whether a lung nodule found on a CT scan is cancer. About 590 people getting lung cancer screening will give blood samples and be followed for 3 years. The goal is to improve how we …

This study is testing whether an artificial intelligence (AI) system can accurately identify different types of lung cancer by analyzing PET/CT scans and patient information like age, smoking history, and tumor markers. Researchers aim to improve how doctors distinguish between s…

This study tests a new radioactive tracer called [18F]-αvβ6-BP for PET scans in 20 adults with non-small cell lung cancer that has spread to the brain. The goal is to see if this scan can find cancer spots better than current methods like MRI or standard PET scans. Participants w…

This early study tests a new imaging agent called FL-261 in 12 adults with advanced cancers (lung, colorectal, head & neck). The agent targets a protein on cancer cells and is tracked by PET or SPECT scans to see if it can find tumors and their spread more accurately than current…

This early-phase study is testing two new radioactive imaging agents (JFI447 and FFG233) to see how well they light up different solid tumors on PET scans. About 66 adults with advanced cancers like pancreatic, lung, breast, colorectal, or sarcoma will receive the agents and unde…

This early-stage study tests a new imaging drug called [18F]DK222 in 6 people with lung or bladder cancer. The drug is designed to attach to a protein (PD-L1) that cancers use to hide from the immune system. The main goal is to check the drug's safety and how it moves through the…

This study is testing a new type of PET scan that uses a special probe (68Ga-TOI-1) to find lung cancer cells. The probe targets a protein called CDH3, which is only found on cancer cells, potentially making the scan more accurate than current methods. About 80 adults with suspec…

This study tests whether a special microscope (CLE) can help doctors identify non-small cell lung cancer in real time during a biopsy. About 70 adults with suspected lung tumors will have standard biopsy plus CLE imaging. Researchers will compare the CLE score to standard lab res…

This study tests a new imaging agent (68GaNOTA-anti-MMR-VHH2) that may help doctors see certain immune cells called macrophages in lung cancer tumors using a PET scan. About 20 adults with non-small cell lung cancer who are scheduled for surgery will receive the agent before thei…

This study involves 200 people with stage II-IIIB lung cancer who will receive standard chemotherapy or immunotherapy before surgery. Researchers will use a special PET scan (FAPI-PET) and a fluorescent dye during surgery to make cancer cells glow, helping surgeons see exactly wh…

This study is testing a new imaging agent called 18F-T2, which is used in a PET/CT scan to find tumors that have high levels of a protein called CAIX. The goal is to see if this scan is better than standard scans at detecting and staging several types of cancer, including kidney,…

This study tests whether using a smaller chest drain (16F) instead of the standard larger one (24F) can reduce pain after minimally invasive lung surgery for cancer. About 124 adults having lung lobe or segment removal will be randomly assigned to one drain size. The main goal is…

This study tests a 12-week home-based coaching program for people with early-stage lung cancer who have had surgery. Participants wear a Fitbit and get personalized step goals and coach calls to help them increase daily walking. The goal is to see if this support helps patients b…

This study tests a mobile app that guides lung cancer patients and their family caregivers through yoga exercises at home. The goal is to see if the app is safe, easy to use, and helpful during radiation treatment. About 60 patient-caregiver pairs will participate.

This study tests a new radiation technique called lattice radiation therapy (LRT) for people with solid tumors that have spread to soft tissues. The goal is to see if LRT works better than standard radiation at shrinking tumors and helping the immune system fight cancer. About 26…

This study tests whether online singing training can improve physical function, reduce symptoms, and boost quality of life in people who had surgery for early-stage lung cancer 6 to 18 months ago. About 100 participants will be randomly assigned to either online singing sessions …

This study tests whether a mix of home and center exercise sessions works as well as all-center sessions for people with non-small cell lung cancer before surgery. About 38 adults will take part, doing 15 exercise sessions over three weeks. The goal is to see if the hybrid approa…

This study tests a new drug, JMT203, for people with cancer who are losing weight and muscle (cachexia). The goal is to see if it is safe and helps patients gain or maintain weight. About 307 adults with lung or pancreatic cancer will take part. The drug is given as an injection,…

This study follows 180 people with early-stage lung cancer to see if a smaller surgery (segmentectomy) leads to less shortness of breath and better quality of life compared to a larger surgery (lobectomy). Participants answer questionnaires before surgery and at several points du…

This study tests whether a new version of megestrol acetate can help people with advanced lung cancer maintain their appetite and body weight while undergoing chemotherapy and radiation. About 134 participants will receive either the study drug or a placebo alongside standard can…

This study looks at whether a simple exercise program is practical and helpful for people with non-small cell lung cancer who are getting radiation therapy, along with their family caregivers. About 40 pairs (patient and caregiver) will take part. The goal is to see if exercising…

This study tests whether a special immune-boosting nutrition drink can lower the chance of severe throat and esophagus inflammation (esophagitis) in lung cancer patients getting chest radiation. About 121 adults with lung cancer will either receive standard care or the immunonutr…

This study tests whether a supervised exercise program is safe and doable for people with lung cancer who are receiving radiation and chemotherapy. Ten participants will do breathing exercises, walking or cycling, and light strength training during their treatment. The goal is to…

This study tests a technique using a fluorescent dye to help surgeons see exactly which part of the lung to remove during robotic surgery for early-stage lung cancer. The goal is to remove only the small cancerous segment instead of an entire lobe, saving healthy lung tissue. Abo…

This study looks at whether pulmonary rehabilitation—a program of exercise and breathing techniques—can improve breathing, fatigue, and quality of life for people with advanced non-small cell lung cancer. Half of the 85 participants will do an 8-week rehab program, while the othe…

This study tests a new way to remove small lung tumors using a 3D computer model and a dye that makes the tumor glow during surgery. The goal is to help surgeons remove only the diseased part of the lung, avoiding a full lobe removal. About 32 adults with early-stage lung cancer …

This study compares two ways to give breathing exercises to people with non-small cell lung cancer before and after lung surgery. Half of the 560 participants will use a smartphone app called Fissios along with in-person physiotherapy sessions, while the other half will only atte…

This early study tests a special imaging agent called [89Zr]Zr-DFO-emapalumab that targets a protein (IFN-γ) linked to cancer. Six adults with untreated non-small cell lung cancer will get a PET scan before and about 30 days after starting immunotherapy. The goal is to see if thi…

This study looks at why some lung cancer cells survive targeted treatment. Researchers will take small tissue samples (biopsies) from 100 patients before and two weeks after starting therapy. By comparing the samples, they hope to find early signs of resistance and identify ways …

This study tests whether an artificial intelligence (AI) model can help doctors make better treatment decisions for non-small cell lung cancer (NSCLC). About 300 patients will have their treatment plans created by both a standard team of doctors and the AI. Researchers will compa…

This study looks at 60 adults with early-stage non-small cell lung cancer whose cancer came back after surgery and treatment with the drug osimertinib. Researchers will analyze tumor or blood samples to find genetic changes linked to the recurrence. The goal is to better understa…

This study looks at whether regularly measuring the amount of pembrolizumab (an immunotherapy drug) in the blood can help doctors better treat non-small cell lung cancer. The goal is to see if this monitoring can improve how well the drug works and reduce side effects. About 75 a…

This study tests whether a new technology called Markerless Tumour Tracking can accurately guide lung cancer radiotherapy without the need for implanted markers. About 30 people with early-stage lung cancer or limited lung metastases will participate. The goal is to see if the ne…

This study is testing a new, noninvasive technology called an electronic nose (E-nose) that analyzes chemicals in a person's breath. Researchers want to see if it can accurately measure how well standard treatment works in people with non-small cell lung cancer and detect if the …

This study is observing 500 adults aged 70 and older who are starting their first treatment for non-small cell lung cancer. Researchers will track how well standard treatments work, their side effects, and how they affect quality of life. The goal is to gather real-world data to …

This study follows 500 adults with advanced non-small cell lung cancer who are prescribed cemiplimab (Libtayo) as part of their normal care. Researchers will track how long patients live, how their tumors respond, and any side effects. The goal is to see how well the drug works o…

This study is for people aged 70 and older with early-stage lung cancer who are scheduled for surgery. Researchers want to see if markers of aging (like changes in DNA and cell health) can help predict who will have complications or need unplanned hospital stays. The goal is to u…

This study looks at whether a special PET scan can tell early on if immunotherapy (with or without chemo) is working for advanced lung cancer. It aims to tell the difference between true tumor growth and harmless inflammation that can look like growth. About 200 adults with non-s…

This study uses surveys to find out what factors patients and doctors in China consider most important when choosing the first targeted therapy for advanced non-small cell lung cancer. About 590 participants (patients and physicians) will share their preferences through a special…

This study is observing 50 people with advanced cancers (like lung, breast, or colon) who are starting immunotherapy. Researchers want to see if changes in a blood marker called ctDNA can predict early on whether the treatment is working. They will also look at other tumor marker…

This study is testing whether a simple rectal mucus sample can detect DNA changes linked to lung, pancreatic, bladder, and colorectal cancers. Researchers will collect samples from 450 adults using a special device and analyze them for genetic and epigenetic markers. The goal is …

This study is not testing a new treatment. Instead, it follows about 130 adults with advanced EGFR-mutant non-small cell lung cancer who are starting standard therapy (osimertinib). Researchers will collect information on how long the cancer stays under control and how long patie…

This study looks at how a 12-week exercise program affects the immune system of people with lung cancer. Researchers will compare two types of exercise (moderate vs. high intensity) to standard care. They will measure changes in immune cells and other markers in the blood to see …

This study is not testing a new treatment. Instead, it watches about 538 people with advanced EGFR-mutated non-small cell lung cancer who are already receiving standard care with osimertinib, with or without chemotherapy. The goal is to see how safe and effective these treatments…

This study looks at whether adding febuxostat (a gout medicine) to the standard lung cancer drug osimertinib can increase the amount of osimertinib that reaches the brain. It involves 7 adults with a specific type of advanced lung cancer who are already taking osimertinib. Resear…

This study aims to understand why some ROS1-positive non-small cell lung cancers stop responding to the drug entrectinib. Researchers will analyze tumor or blood samples from 38 patients who have already taken entrectinib as part of their regular care. By looking at the genetic c…

This study collects tumor tissue and blood cells from 200 adults with advanced solid tumors like colorectal, lung, or pancreatic cancer. The goal is to understand which cancers might respond to a future CAR T-cell therapy and to store participants' own immune cells for potential …

This study looks at how the body's metabolism influences whether immunotherapy works in people with non-small cell lung cancer (NSCLC). Researchers will collect and analyze tissue samples from 150 patients to find patterns linked to treatment response or resistance. The goal is t…

This study looks at whether a lab-grown model of a patient's own lung cancer cells can help doctors choose the most effective drugs. Researchers will compare the model's predictions with how the patient actually responds to treatment. The goal is to see if this approach can guide…

This observational study will follow about 500 adults in Spain with EGFR-mutated non-small cell lung cancer who are taking the drug osimertinib. Researchers want to see how well the drug works in everyday medical practice, including survival rates, treatment adherence, and qualit…

This study collects blood samples and health information from 1,200 people with non-small cell lung cancer. Researchers want to learn how the cancer changes during standard treatment and whether simple blood tests can predict if the cancer will come back. Participants continue th…

This study looks at the biological features of a specific type of lung cancer (ALK-positive) in 100 patients. Researchers will analyze tumor samples and blood tests taken at diagnosis and when the disease worsens. The goal is to learn why some treatments stop working, not to test…

This study aims to find biological markers (biomarkers) in the blood and tumors of people with non-small cell lung cancer that can predict whether immunotherapy will work. Researchers will compare these markers between people whose cancer responds and those whose does not. The go…

This study asks people with certain cancers whether they prefer getting their immunotherapy (nivolumab or pembrolizumab) as a quick shot under the skin or as a longer IV infusion. About 880 participants will try both methods and share their preference. The goal is to understand w…

This study is collecting tumor and blood samples from 1,100 people with various cancers (head and neck, ovarian, cervical, lung, brain, and anal) to measure how active certain immune cells are. The goal is to better understand why some cancers trigger a stronger immune response t…

This study uses machine learning to analyze real-world data from over 144,000 people with advanced non-small cell lung cancer. The goal is to find which existing treatments work best for different patient groups, helping doctors make more personalized choices. Participants' healt…

This study aims to understand cancer-related fatigue in people with non-small cell lung cancer who are receiving immunotherapy. Researchers will interview 20 patients about their fatigue, daily function, and views on physical activity. The goal is to learn how fatigue affects pat…

This observational study looks at 300 people with early-stage lung cancer to understand why different types of the disease behave differently. Researchers will analyze genes, immune cells, and other markers from tumor samples. The goal is to find patterns that could lead to bette…

This study reviews medical records of 150 patients with inoperable lung cancer that returned after previous radiation. Researchers want to learn if giving another round of high-precision radiation (SBRT) is safe and effective. The goal is to help doctors make better treatment dec…

This study looks at whether adding a simple blood test that detects tumor DNA (ctDNA) to regular scans can help doctors choose better treatments for people with advanced colorectal or non-small cell lung cancer. About 332 adults with cancer that has spread will be randomly assign…

This study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancer works and why some cancers respond differently to treatment. The goal is to develop more effective …

This study looks at whether immunotherapy drugs (anti-PD-1) can weaken bones and increase fracture risk in people being treated for cancer. About 25 adults with various cancers will have their bone density and blood markers measured over a year. The goal is to gather information …

This study aims to collect and analyze tumor tissue from 550 adults with advanced non-small-cell lung cancer in Taiwan. Researchers will use genetic sequencing to understand why some patients stop responding to targeted drugs and to find new treatment options. The goal is to crea…

This study tests whether a natural supplement called urolithin A (MitoPure®) can improve the immune response in people with solid tumors like lung cancer or melanoma who are starting standard immunotherapy. About 45 participants will be randomly assigned to take either the supple…

This study is testing whether an artificial intelligence (AI) tool can help match cancer patients with the right clinical trials. Researchers will enroll up to 50,000 people with various cancers to see if the AI improves trial enrollment rates and patient outcomes. The goal is to…

This study looks at why the drug amivantamab stops working in people with a specific type of advanced lung cancer (NSCLC with EGFR exon 20 insertion). Researchers will collect blood and tumor samples from 30 patients when their disease gets worse while on the drug. The goal is to…

This study tests a new way to predict how well your lungs will work after lung cancer surgery. Doctors will use 3D CT scans to create a virtual model of your lungs and simulate the surgery beforehand. The goal is to see if this method is more accurate than current techniques, hel…

This study is observing 300 adults with kidney, bladder, lung, or liver cancer who are starting immunotherapy (PD-1/PDL-1 inhibitors). Researchers will measure a protein called Galectin-3 in the blood before each treatment to see if its level is linked to how well the therapy wor…

This study uses lab-grown tumor models from lung cancer patients to test new natural compounds (resveratrol and artichoke extract). The goal is to see if these compounds can make immunotherapy more effective and reduce side effects. Only 5 patients will provide tissue samples; no…

This study watches 100 adults with metastatic non-small cell lung cancer who have certain EGFR gene changes and are already getting amivantamab plus chemotherapy through an early access program. Researchers want to see how long the cancer stays under control in real-world setting…

This study collects tumor tissue, blood, and other samples from 2,000 adults with certain lung and thymic cancers. Researchers will use these samples to learn more about how these cancers grow and change over time. The goal is to find new ways to diagnose and treat these diseases…

This study aims to learn more about lung cancer in adults diagnosed at age 45 or younger. Researchers will collect blood samples and medical information from 500 participants to study the biology of these cancers and look for genetic changes that could lead to better treatments. …

This study looks at blood, urine, and bone marrow samples from 620 people with solid cancers (like lung, colon, or pancreatic cancer) to find and measure tumor cells and DNA. The goal is to better understand how cancer spreads and returns after surgery. Participants include cance…

This study looks at the gut microbiome (bacteria in your digestive system) in people with advanced non-small cell lung cancer. Researchers want to see if the types and amounts of gut bacteria are linked to how well treatment works and what side effects occur. About 82 participant…

This study collects samples from 320 people, including cancer patients and those undergoing lung cancer screening, to measure tumor cells and DNA in blood, urine, and bone marrow. The goal is to learn more about how cancer spreads and to improve early detection and personalized t…

This study does not test a new treatment. Instead, it collects information from 550 people with advanced lung cancer who are receiving standard therapies. The goal is to create detailed control groups that can be used in future clinical trials, making them more accurate and effic…

This study looks at whether the kind of anesthesia used during lung cancer surgery affects the chances of the cancer coming back. About 5,384 people having surgery for early-stage non-small cell lung cancer will be randomly assigned to receive either inhaled gas anesthesia or int…